James Brett Case

List of Publications by Citations

64	5,911	28	69
papers	citations	h-index	g-index
69	9,420	25.1	5.96
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
64	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*, **2020**, 583, 290-295	50.4	1028
63	Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature*, **2020**, 584, 443-449	50.4	609
62	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nature Medicine*, **2021**, 27, 717-726	50.5	497
61	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. *Cell*, **2020**, 182, 744-753.e4	56.2	337
60	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science*, **2020**, 370, 950-957	33.3	314
59	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nature Medicine*, **2020**, 26, 1422-1427	50.5	283
58	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. *Nature Immunology*, **2020**, 21, 1506-1516	19.1	272
57	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. *Cell Host and Microbe*, **2020**, 28, 475-485.e5	23.4	252
56	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell*, **2020**, 183, 169-184.e13	56.2	221
55	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. *Science*, **2020**, 370, 426-431	33.3	219
54	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. *Nature*, **2021**, 596, 109-113	50.4	203
53	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. *Cell*, **2021**, 184, 1804-1820.e16	56.2	149
52	The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell*, **2021**, 184, 2183-2200.e22	56.2	145
51	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *Journal of Immunology*, **2020**, 205, 915-922	5.3	126
50	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. *Cell Host and Microbe*, **2020**, 28, 465-474.e4	23.4	106
49	Growth, detection, quantification, and inactivation of SARS-CoV-2. *Virology*, **2020**, 548, 39-48	3.6	99
48	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 32105-32113	11.5	96

47	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. *Nature*, **2021**, 596, 103-108	50.4	91
46	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.. *Nature*, **2022**,	50.4	89
45	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 20803-20813	11.5	87
44	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. *Nature Microbiology*, **2021**, 6, 1233-1244	26.6	72
43	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. *Clinical Chemistry*, **2020**, 66, 1538-1547	5.5	70
42	Structural and functional analysis of a potent sarbecovirus neutralizing antibody **2020**,		42
41	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. *Cell Reports Medicine*, **2021**, 2, 100230	18	40
40	SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies **2021**,		39
39	A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. *Cell Reports*, **2021**, 36, 109400	10.6	35
38	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. *Immunity*, **2021**, 54, 2399-2416.e6	32.3	30
37	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection **2020**,		29
36	Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail **2021**,		28
35	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. *Immunity*, **2021**, 54, 2159-2166.e6	32.3	27
34	LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. *Nature*, **2020**, 588, 308-314	50.4	22
33	A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters **2020**,		18
32	On the road to ending the COVID-19 pandemic: Are we there yet?. *Virology*, **2021**, 557, 70-85	3.6	18
31	The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. **2021**,		17
30	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.. *Cell Reports*, **2021**, 37, 110143	10.6	16

29	SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice. *Journal of Virology*, **2021**, JVI0151121	6.6	15
28	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. *Cell Host and Microbe*, **2021**,	23.4	14
27	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity **2021**,		13
26	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. *SSRN Electronic Journal*, **2020**, 3606354	1	12
25	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. *Cell Host and Microbe*, **2021**, 29, 1151-1161.e5	23.4	11
24	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 **2020**,		10
23	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. *Journal of Molecular Biology*, **2021**, 433, 167177	6.5	10
22	Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis **2020**,		9
21	A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants **2021**,		9
20	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. *Science Translational Medicine*, **2022**, 14,	17.5	9
19	JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis **2021**,		8
18	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations **2020**,		8
17	Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice. **2022**,		6
16	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. *Cell Reports*, **2021**, 37, 109881	10.6	6
15	A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope **2021**,		6
14	A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection		5
13	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques **2021**,		5
12	SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans		4

List of Publications

11	Multivalent designed proteins protect against SARS-CoV-2 variants of concern **2021**,		4
10	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.. *Cell*, **2022**,	56.2	3
9	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains		3
8	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. *Science Translational Medicine*, **2022**, 14, eabn1252	17.5	3
7	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.. *MBio*, **2022**, e0337721	7.8	2
6	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains **2021**,		2
5	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.. *MBio*, **2022**, e0323821	7.8	1
4	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice **2021**,		1
3	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting.. *Cell Reports*, **2022**, 110561	10.6	1
2	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.. *Journal of Clinical Investigation*, **2022**,	15.9	1
1	Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies. *Cell Reports*, **2022**, 110905	10.6	0